AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NASDAQ:NLTXNeoleukin Therapeutics Stock Price, Forecast & News

$12.93
-1.00 (-7.18 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.90
Now: $12.93
$13.90
50-Day Range
$12.10
MA: $13.94
$17.05
52-Week Range
$2.37
Now: $12.93
$18.13
Volume328,000 shs
Average Volume402,085 shs
Market Capitalization$496.33 million
P/E RatioN/A
Dividend YieldN/A
Beta-4.41
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NLTX
CUSIPN/A
CIKN/A
Phone206-732-2133

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$2.91 per share

Profitability

Net Income$-69,440,000.00

Miscellaneous

Employees8
Market Cap$496.33 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive NLTX News and Ratings via Email

Sign-up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.

Neoleukin Therapeutics (NASDAQ:NLTX) Frequently Asked Questions

How has Neoleukin Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NLTX stock has increased by 62.4% and is now trading at $12.93. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neoleukin Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neoleukin Therapeutics.

When is Neoleukin Therapeutics' next earnings date?

Neoleukin Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Neoleukin Therapeutics.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics (NASDAQ:NLTX) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. View Neoleukin Therapeutics' earnings history.

What price target have analysts set for NLTX?

6 Wall Street analysts have issued 12-month price targets for Neoleukin Therapeutics' shares. Their forecasts range from $18.00 to $28.00. On average, they expect Neoleukin Therapeutics' share price to reach $21.50 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price. View analysts' price targets for Neoleukin Therapeutics.

Has Neoleukin Therapeutics been receiving favorable news coverage?

News coverage about NLTX stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neoleukin Therapeutics earned a news sentiment score of -2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Neoleukin Therapeutics.

Who are some of Neoleukin Therapeutics' key competitors?

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Calithera Biosciences (CALA), Canopy Growth (CGC), Intra-Cellular Therapies (ITCI), InVitae (NVTA), ACADIA Pharmaceuticals (ACAD), Athenex (ATNX), Five Prime Therapeutics (FPRX), Gilead Sciences (GILD), ImmunoGen (IMGN) and Pfizer (PFE).

Who are Neoleukin Therapeutics' key executives?

Neoleukin Therapeutics' management team includes the following people:
  • Mr. David J. Main, Co-Founder, Chairman & Pres (Age 54)
  • Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)
  • Dr. Jonathan G. Drachman, Chief Exec. Officer (Age 57)
  • Ms. Shelley McCloskey, VP of HR & Admin. (Age 59)

What is Neoleukin Therapeutics' stock symbol?

Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neoleukin Therapeutics' stock price today?

One share of NLTX stock can currently be purchased for approximately $12.93.

How big of a company is Neoleukin Therapeutics?

Neoleukin Therapeutics has a market capitalization of $496.33 million and generates $25 million in revenue each year. The company earns $-69,440,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Neoleukin Therapeutics employs 8 workers across the globe.

What is Neoleukin Therapeutics' official website?

The official website for Neoleukin Therapeutics is www.neoleukin.com.

How can I contact Neoleukin Therapeutics?

Neoleukin Therapeutics' mailing address is SUITE 360 - 1616 EASTLAKE AVE EAST, SEATTLE WA, 98102. The company can be reached via phone at 206-732-2133 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.